Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13859223 | 0.87 | MEN1 (0.51) | ALDH1A1L3MBTL1LMNAPOLBHSD17B10 | |
| SCHEMBL3463258 | 0.80 | ALDH1A1 (0.60) | ALDH1A1L3MBTL1LMNAPOLBHSD17B10 | |
| SCHEMBL29623887 | 0.79 | RIPK1 (0.46) | ALDH1A1L3MBTL1LMNAPOLBHSD17B10 | |
| SCHEMBL13434089 | 0.79 | KMT2A (0.77) | ALDH1A1L3MBTL1LMNAPOLBHSD17B10 | |
| SCHEMBL28515137 | 0.78 | LMNA (0.47) | ALDH1A1L3MBTL1LMNAPOLBHSD17B10 | |
| SCHEMBL17393246 | 0.78 | LMNA (0.47) | ALDH1A1L3MBTL1LMNAPOLBHSD17B10 | |
| SCHEMBL737633 | 0.75 | MEN1 (0.49) | ALDH1A1L3MBTL1LMNAPOLBHSD17B10 | |
| SCHEMBL3462963 | 0.75 | LMNA (0.57) | ALDH1A1L3MBTL1LMNAPOLBHSD17B10 | |
| SCHEMBL3463311 | 0.75 | MEN1 (0.53) | ALDH1A1L3MBTL1LMNAPOLBHSD17B10 | |
| SCHEMBL15855771 | 0.74 | KMT2A (0.47) | ALDH1A1L3MBTL1LMNAPOLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725407-B2 | HDAC inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-20160137594-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2016-05-19 | — | — | US | disclosed |
| US-9273003-B2 | Methods of treating lymphoma and rheumatoid arthritis with cyclopentyl (2S)-cyclohexyl[({6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl}methyl)amino]acetate | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-20140323531-A1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2014-10-30 | — | — | US | disclosed |
| US-8637547-B2 | Compounds which inhibit members of the histone deacetylase family of enzymes and their use in the treatment of cell proliferative diseases | CHROMA THERAPEUTICS LTD. (GB) | 2014-01-28 | — | — | US | disclosed |
| US-20130197042-A1 | HDAC INHIBITORS | CHROMA THERAPEUTCS, LTD | 2013-08-01 | — | — | US | disclosed |
| US-20100010010-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323531-A1 | HDAC INHIBITORS | HDAC1, HDAC3, HDAC2 | ALDH1A1 626/4885L3MBTL1 765/4885LMNA 587/4885 |
| US-20100010010-A1 | HDAC INHIBITORS | HDAC1, HDAC3, HDAC2 | ALDH1A1 634/4885L3MBTL1 757/4885LMNA 573/4885 |
| US-20160137594-A1 | HDAC INHIBITORS | HDAC1, HDAC11, HDAC2 | ALDH1A1 638/4885L3MBTL1 453/4885LMNA 319/4885 |
| US-20130197042-A1 | HDAC INHIBITORS | HDAC1, HDAC3, HDAC2 | ALDH1A1 626/4885L3MBTL1 765/4885LMNA 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.